2. Academic Validation
  3. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

  • Cancer Cell. 2015 Jul 13;28(1):42-56. doi: 10.1016/j.ccell.2015.05.007.
Colin A Flaveny 1,  Kristine Griffett 2,  Bahaa El-Dien M El-Gendy 3,  Melissa Kazantzis 4,  Monideepa Sengupta 2,  Antonio L Amelio 5,  Arindam Chatterjee 2,  John Walker 2,  Laura A Solt 4,  Theodore M Kamenecka 4,  Thomas P Burris 6
Affiliations

Affiliations

  • 1 Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA. Electronic address: [email protected].
  • 2 Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
  • 3 Chemistry Department, Faculty of Science, Benha University, Benha 13518, Egypt.
  • 4 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458, USA.
  • 5 Lineberger Comprehensive Cancer Center, Biomedical Research Imaging Center, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA.
  • 6 Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63310, USA. Electronic address: [email protected].
PMID: 26120082 DOI: 10.1016/j.ccell.2015.05.007
Abstract

Malignant cells exhibit aerobic glycolysis (the Warburg effect) and become dependent on de novo lipogenesis, which sustains rapid proliferation and resistance to cellular stress. The nuclear receptor liver-X-receptor (LXR) directly regulates expression of key glycolytic and lipogenic genes. To disrupt these oncogenic metabolism pathways, we designed an LXR inverse agonist SR9243 that induces LXR-corepressor interaction. In Cancer cells, SR9243 significantly inhibited the Warburg effect and lipogenesis by reducing glycolytic and lipogenic gene expression. SR9243 induced Apoptosis in tumors without inducing weight loss, hepatotoxicity, or inflammation. Our results suggest that LXR inverse agonists may be an effective Cancer treatment approach.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16972
    98.88%, LXR Inverse Agonist
    LXR